View Expired Tender

Get immediate access to tenders like the one below by subscribing now to Tenders Direct. We will set up your personalised profile and send you tender alerts direct to your mailbox as soon as they are published. You will also benefit from having access to historical tenders.

Notice Summary

Title:
United Kingdom-Belfast: Development of a Liposomal Formulation of a Peptide for Inhalation
Document Ref:
190205-2019
Document Type:
Contract Notice - Open Procedure
Published By:
Queen's University Belfast
Date Published:
23 April 2019
Deadline Date:
03 June 2019
Document Source:
Framework/DPS:
No
Alert Profile:
Labels:

Notice Abstract

The iABC-consortium (inhaled Antibiotics in Bronchiectasis and Cystic fibrosis) brings together world leading researchers to develop new antibiotic treatment options for people with Cystic Fibrosis (CF) and Bronchiectasis (BE), by sharing expertise and resources. The iABC program provides a unique opportunity to address a critical bottleneck in the development of antimicrobial agents for the treatment of chronic lung infection in CF and BE patients. This work has the potential to deliver new treatments which will improve quality of life and survival of CF and BE patients. As part of this program, Queens University Belfast seeks to appoint an Economic Operator to provide services to conduct Liposomal Formulation of a Peptiide for Inhalation sponsored by Polyphor Ltd.

Notice Details

Contract notice

Directive 2014/24/EU - Public Sector Directive

Directive 2014/24/EU

Section I: Contracting Change entity

I.1) Name and addresses

Queen's University Belfast

University Road

Belfast

BT7 1NN

UK

Contact person: Mrs Gillian Wasson

Telephone: +44 2890973026

E-mail: g.wasson@qub.ac.uk

NUTS: UKN

Internet address(es)

Main address: https://www.qub.ac.uk/directorates/FinanceDirectorate/Visitors/Procurement/

Address of the buyer profile: https://in-tendhost.co.uk/queensuniversitybelfast/aspx/Home

I.3) Communication

Access to the procurement documents is restricted. Further information can be obtained at:

https://in-tendhost.co.uk/queensuniversitybelfast/aspx/Home


Additional information can be obtained from the abovementioned address


Tenders or requests to participate must be sent electronically to:

https://in-tendhost.co.uk/queensuniversitybelfast/aspx/Home


Tenders or requests to participate must be sent to the abovementioned address


I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Education

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

QUB/1820/19 Development of a Liposomal Formulation of a Peptide for Inhalation

Reference number: QUB/1820/19

II.1.2) Main CPV code

85121200

 

II.1.3) Type of contract

Services

II.1.4) Short description

The iABC-consortium (inhaled Antibiotics in Bronchiectasis and Cystic fibrosis) brings together world leading researchers to develop new antibiotic treatment options for people with Cystic Fibrosis (CF) and Bronchiectasis (BE), by sharing expertise and resources. The iABC program provides a unique opportunity to address a critical bottleneck in the development of antimicrobial agents for the treatment of chronic lung infection in CF and BE patients. This work has the potential to deliver new treatments which will improve quality of life and survival of CF and BE patients. As part of this program, Queens University Belfast seeks to appoint an Economic Operator to provide services to conduct Liposomal Formulation of a Peptiide for Inhalation sponsored by Polyphor Ltd.

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.2) Additional CPV code(s)

85121200

II.2.3) Place of performance

NUTS code:

UKN

Main site or place of performance:

II.2.4) Description of the procurement

The iABC-consortium (inhaled Antibiotics in Bronchiectasis and Cystic fibrosis) brings together world leading researchers to develop new antibiotic treatment options for people with Cystic Fibrosis (CF) and Bronchiectasis (BE), by sharing expertise and resources. The iABC program provides a unique opportunity to address a critical bottleneck in the development of antimicrobial agents for the treatment of chronic lung infection in CF and BE patients. This work has the potential to deliver new treatments which will improve quality of life and survival of CF and BE patients. As part of this program, Queens University Belfast seeks to appoint an Economic Operator to provide services to conduct Liposomal Formulation of a Peptiide for Inhalation sponsored by Polyphor Ltd. Applicants seeking to obtain tender documents must first complete and submit a Confidential Disclosure Agreement (CDA). Please note: tender documents will not be issued to any applicant until they have first submitted a completed CDA to Queen's University Belfast via the electronic tendering system outlined within this notice. The CDA may be obtained from the contact details outlined within this notice. It is anticipated that all applicants who have completed a CDA will receive tender documentation on 1.5.2019, with a closing date for receipt of tenders on 3.6.2019 at 4:00 p.m. (BST).

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 6

This contract is subject to renewal: No

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: Yes

II.2.11) Information about options

Options: Yes

Description of options:

Option to extend the contract by a further period of 12 months.

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: Yes

II.2.14) Additional information

Section III: Legal, economic, financial and technical information

III.1) Conditions for participation

III.1.1) Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers

List and brief description of conditions:

III.1.2) Economic and financial standing

Selection criteria as stated in the procurement documents

III.1.3) Technical and professional ability

Selection criteria as stated in the procurement documents

III.2) Conditions related to the contract

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.8) Information about Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.2) Time limit for receipt of tenders or requests to participate

Date: 03/06/2019

Local time: 16:00

IV.2.4) Languages in which tenders or requests to participate may be submitted

EN

IV.2.7) Conditions for opening of tenders

Date: 03/06/2019

Local time: 16:30

Place:

Section VI: Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.2) Information about electronic workflows

Electronic ordering will be used

Electronic payment will be used

VI.4) Procedures for review

VI.4.1) Review body

Queen's University Belfast

University Road

Belfast

BT7 1NN

UK

VI.4.3) Review procedure

Precise information on deadline(s) for review procedures:

This Authority will incorporate a standstill period at the point information on the award of the contract is communicated to Tenderers. That notification will provide full information on the award decision. The standstill period, which will be for a minimum of 10 calendar days, provides time for unsuccessful tenderers to challenge the award decision before the contract is entered into. The Public Contract Regulations 2015 (SI 2015/102) provide for aggrieved parties who have been harmed or are at risk of harm by a breach of the rules to take action in the High Court (England, Wales and Northern Ireland).

VI.5) Date of dispatch of this notice

18/04/2019

Current Notes